Penetrating keratoplasty for varicella-zoster virus keratopathy

The treatment of end-stage corneal disease: penetrating keratoplasty compared with Boston type 1 keratoprosthesis

Penetrating keratoplasty (PKP) yields excellent results for restoring vision in end-stage corneal diseases. However, its success is limited to high-risk diseases such as aniridia, chemical burns, autoimmune corneal diseases, and herpetic eye disease. Boston type 1 keratoprosthesis (BKPro) offers another option to these patients. Since 1992, improvements in perioperative management and device construction have significantly increased the use of BKPro worldwide and challenged the therapeutic role of PKP in these patients. This review aims to evaluate BKPro's place in the treatment algorithm of these high-risk patients to assist surgeons' decision-making. PKP and BKPro are compared in three outcome categories: visual acuity, graft retention and failure, and complications profile. Special attention is given to comparing secondary BKPro versus repeated PKP as well as primary BKPro versus primary PKP. We conclude that secondary BKPro bears a better prognosis than repeated PKP in most high-risk patients. Similarly, primary BKPro likely confers improved outcomes over primary PKP in most high-risk recipients. However, current evidence is based on retrospective designs, and controlled prospective randomized trials are required to validate these conclusions.

A retrospective study comparing DALK and PKP in the treatment of necrotizing stromal keratitis

PURPOSE

To compare the clinical outcomes of deep anterior lamellar keratoplasty (DALK) and penetrating keratoplasty (PKP) in the treatment of necrotizing stromal keratitis (NSK).

METHODS

A retrospective study of NSK patients who underwent keratoplasty between January 2015 and December 2017 in the Third Xiangya Hospital was carried out. Data including preoperative and postoperative best corrected visual acuity (BCVA), intraocular pressure, graft survival rates, corneal endothelial cell density, corneal topography and thickness were reviewed and analyzed by SPSS 23.0 software.

RESULTS

Fifty patients were involved. Twenty-five patients received DALK, and the other half received PKP. The average follow-up period was 10.28 ± 5.92 months. At the end of the follow-up period, there were no significant differences in postoperative BCVA, recurrence of virus, graft rejection or graft failure between the two groups. There were also no significant differences in average central corneal thickness postoperatively at 3 months. However, the average corneal endothelial cell density at 3 months was significantly higher in the DALK group (2121.12 ± 450.80 cell/mm² in the DALK group versus 1812.16 ± 340.38 cell/mm² in the PKP group, P = 0.009).

CONCLUSION

Both DALK and PKP could increase visual acuity and prevent the progression of NSK. There were no significant differences between DALK and PKP in postoperative BCVA, rate of rejection, graft failure or recurrence rate. DALK significantly reduced the loss of corneal endothelial cells.

Boston keratoprosthesis type 1 for herpes simplex and herpes zoster keratopathy

PURPOSE

The aim of this study was to evaluate and compare the outcomes of Boston keratoprosthesis type 1 (Kpro-1) in eyes with herpes simplex virus (HSV) and herpes zoster virus (HZV) keratopathy.

METHODS

A retrospective review was performed of the medical records of every patient treated with a Boston Kpro-1 at the University of Iowa Hospitals and Clinics between January 1, 2008 and July 1, 2012. Eyes with visual loss due to HSV or HZV keratopathy were included in the statistical analysis. The main outcome measures were graft retention, postoperative complications, and visual outcome.

RESULTS

Nine eyes met the inclusion criteria, including 5 eyes in the HSV group and 4 eyes in the HZV group. The graft retention rate was 100% in the HSV group after a mean follow-up of 48.4 months, compared with 25% in the HZV group after 50.5 months (P = 0.048). There were 3 cases of microbial keratitis, including 2 eyes that also developed endophthalmitis, in the HZV group, compared with no cases in the HSV group (P = 0.048). There was significantly better best-corrected visual acuity at the most recent examination in the HSV group than in the HZV group (P = 0.019). All 5 HSV eyes had improved best-corrected visual acuity compared with preoperative acuity, whereas only 1 HZV eye experienced a similar result (P = 0.048).

CONCLUSIONS

Kpro-1 is associated with an excellent prognosis for graft retention, acceptably low prevalence of sight-threatening complications, and highly satisfactory visual improvement in eyes with HSV keratopathy, but not in eyes with HZV keratopathy.

New insights into the diagnosis and treatment of neurotrophic keratopathy

Abnormalities of the ocular surface can be acquired or inherited disorders of the central nervous system. Loss of neural stimulation from the sensory division of the trigeminal nerve or from the autonomic nervous system can have devastating consequences on corneal epithelial wound healing and the precorneal tear film, leading to decreased vision. The pathogenesis of neurotrophic keratopathy is reviewed, and treatment modalities are recommended.

Elliptical Nonmechanical Corneal Trephination

PURPOSE

To assess intraoperative complications and long-term outcome of elliptical excimer laser trephination for penetrating keratoplasties (EELPKs) performed at the Friedrich-Alexander University of Erlangen, between 1989 and 2002.

METHODS

This was a retrospective, longitudinal, single-center, clinical, interventional case series. Forty-two eyes (14 Fuchs dystrophy, 11 corneal ulcer, 7 aphakic/pseudophakic bullous keratopathy, 9 corneal scars, 1 keratotorus) after EELPK were observed. Trephination was performed with a 193-nm Meditec excimer laser along metal masks with 0-8 orientation teeth/notches. Horizontal/vertical graft diameters ranged from 7.0/6.0 to 8.0/7.0 mm, and 12 to 24 interrupted sutures were used. Simultaneously, 11 eyes (26.2%) underwent cataract surgery, 3 (7.1%) underwent intraocular lens (IOL) exchange, and 1 (2.4%) underwent secondary IOL implantation. The main outcome measures included intraoperative complications, immune reactions, and final astigmatism/visual acuity at the end of follow-up.

RESULTS

During surgery, 4 (9.5%) recipients had iris bleedings, and 10 (23.8%) ring-shaped superficial corneal thermal donor damages were detected. One (2.4%) immunologic graft rejection was seen in Fuchs dystrophy, and 3 (7.1%) in corneal ulcers occurred during follow-up (4.7 +/- 3.2 years). At the end of follow-up, corrected visual acuity (0.1/0.4; P < 0.001) and keratometric astigmatism (2.3 D/4.7 D, P = 0.001) increased significantly.

CONCLUSIONS

In EELPK, intraoperative disadvantages, such as the need for interrupted sutures and a tendency toward higher and more irregular astigmatism, may be expected. This study does not have the power to statistically confirm the tendency of EELPK toward a lower rate of immunologic graft rejections after normal-risk keratoplasty. However, EELPK may have advantages in deep or perforated elliptically shaped corneal ulcers (such as in acanthamoeba keratitis).